Petros is a Men’s Health pharmaceutical company that aims to develop complementary therapeutics designed for a man’s journey, often, we believe, centered around the ones he loves and lives for. Petros aims to revolutionize the art and science behind the way men approach their health emphasizing the critical elements of medication adherence, tolerability, preservation of organic function and the restoration of vitality.
Each element approached within an integrated and interdependent perspective, targeting tangible enhancements to their health outcomes. Ultimately, Petros seeks to establish new foundations to Men’s Health that center around the whole of a man’s life and function.
|Oct 14, 2021||Petros Pharmaceuticals Announces $5.7 Million Registered Direct Offering|
|Sep 23, 2021||Petros Pharmaceuticals to Present at the Benzinga Healthcare Small Cap Conference|
|Sep 10, 2021||Petros Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference|
|Aug 17, 2021||Petros Pharmaceuticals Announces Second Quarter Financial Results and Provides Corporate Update; Reports a 123% Increase in Year Over Year Quarterly STENDRA® (avanafil) Net Sales|
|Aug 12, 2021||Petros Pharmaceuticals to Present at Two Upcoming August Conferences|
|Day Range||1.59 - 1.75|
|52 Week Range||1.56 - 5.96|
|Bid/Ask||1.63 / 1.65|
|Bid/Ask Size||700 X 1,300|
|Market Cap||16.12 million|
|Shares Outstanding||9.83 million|
|Dividend/Yield||0.00 / 0.00%|
|P/E Ratio (TTM)||N/A|